Related Experiment Video
Updated: Mar 24, 2026

An Intact Pericardium Ischemic Rodent Model
Published on: September 2, 2021
Anticardiac Antibodies in Patients with Chronic Pericardial Effusion
Konstantinos Karatolios1, Sabine Pankuweit1, Anette Richter1
1Department of Internal Medicine-Cardiology, Philipps University of Marburg, 35043 Marburg, Germany.
Objectives:
Chronic pericardial effusion may be challenging in terms of diagnosis and treatment. Specific laboratory parameters predicting the frequency and severity of recurrences after initial drainage of pericardial effusion are lacking.
Materials And Methods:
Pericardial fluid (PF) and serum (SE) samples from 30 patients with chronic pericardial effusion (PE) who underwent pericardiocentesis and pericardioscopically guided pericardial biopsy were compared with SE and PF samples from 26 control patients. The levels of antimyolemmal (AMLA) and antifibrillary antibodies (AFA) in PE and SE from patients with pericardial effusion as well as PF and SE from controls were determined and compared.
Results:
AMLAs and AFAs in PF and SE were significantly higher in patients with chronic pericardial effusion than in the control group (AMLAs: p = 0,01 for PF and p = 0,004 for serum; AFAs: p < 0,001 for PF and p = 0,003 for serum). Patients with recurrence of PE within 3 months after pericardiocentesis had significantly higher levels of AMLAs in SE (p = 0,029) than patients without recurrence of PE.
Conclusions:
The identification of elevated anticardiac antibodies in PE and SE indicates increased immunological reactivity in chronic pericardial effusion. High titer serum levels of AMLAs also correlate with recurrence of pericardial effusion.
Related Concept Videos
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis I: Introduction
Pericarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Pericarditis IV: Nursing Management
Myocarditis II: Clinical Features and Diagnostic Tests

